Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.
PaperCitations, authors & open-access status
First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer. is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 57 citations, 2023 year and closed oa status.
57
Citations
2023
Year
closed
OA Status